Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Lack of iron early in life can affect brain's physical structure

Lack of iron early in life can affect brain's physical structure

Advocates react to administration's draft framework to stop Alzheimer's

Advocates react to administration's draft framework to stop Alzheimer's

Exposure to light appears to have therapeutic effects on Alzheimer's patients

Exposure to light appears to have therapeutic effects on Alzheimer's patients

New imaging agent shows promise in detecting signs of AD

New imaging agent shows promise in detecting signs of AD

Nicotine patches may help individuals with early memory loss

Nicotine patches may help individuals with early memory loss

DNA decoder – cheaper and faster

DNA decoder – cheaper and faster

Agilent, Integrated Diagnostics partner to improve protein-based LC/MS assays

Agilent, Integrated Diagnostics partner to improve protein-based LC/MS assays

Disruption of circadian rhythms cause accelerated neurodegeneration and premature death

Disruption of circadian rhythms cause accelerated neurodegeneration and premature death

UCLA researchers identify chemical changes in brains of patients with early-onset Alzheimer's

UCLA researchers identify chemical changes in brains of patients with early-onset Alzheimer's

Tesco selects Cancer Research UK as Charity of the Year in 2012

Tesco selects Cancer Research UK as Charity of the Year in 2012

Nicotine patch may help those with mild dementia

Nicotine patch may help those with mild dementia

ORMOSIL nanoparticles show promise as potential drug delivery vehicle

ORMOSIL nanoparticles show promise as potential drug delivery vehicle

Nicotine patch may help improve mild memory loss in older adults

Nicotine patch may help improve mild memory loss in older adults

Experts want young athletes to become more aware of warning signs of concussion

Experts want young athletes to become more aware of warning signs of concussion

AAN, Wolters Kluwer Health announce launch of Neurology Today for the iPad

AAN, Wolters Kluwer Health announce launch of Neurology Today for the iPad

Nicotine patch may boost memory in individuals with MCI

Nicotine patch may boost memory in individuals with MCI

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

The sharpness of the brain dulls beyond 45: Study

The sharpness of the brain dulls beyond 45: Study

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.